Efficacy and safety of inactivated novel variant infectious bursal disease virus in broiler chickens

Gauthaman, Lathasha (2022) Efficacy and safety of inactivated novel variant infectious bursal disease virus in broiler chickens. [Project Paper] (Submitted)

Text lp FPV 2022 80.pdf Download (2MB)

Abstract

Infectious bursal disease virus (IBDV) is an acute, highly contagious viral infection that causes high mortality and immunosuppression in susceptible chickens and remains as a major threat to the global poultry industry. Recent reports of a novel variant IBDV (nVarIBDV) in poultry farms in China, Japan, South Korea and Malaysia have indicated the need to develop a new vaccine against this strain as the available commercial vaccines are unable to sufficiently protect chickens from the nVarIBDV infection. This study focused on evaluating the efficacy and safety of inactivated nVarIBDV as a potential vaccine candidate in broiler chickens. A total of 65 day-old chickens were divided into three groups namely A, B, and C. They were immunized at day-old (Groups A and B) and booster at day 14 (Group B) with inactivated nVarIBDV (107 EID50/0.2 ml). Group C acted as the control group and remained uninoculated. The chickens in the challenged groups (ACH, BCH and CCH) were challenged with nVarIBDV 105 EID 50/1.0ml on day 28 post inoculation. The body and bursa weights and blood samples of the chickens were collected. Gross lesions were recorded and samples of bursa of Fabricius were collected for histological evaluation. The study showed that the chickens were healthy and normal throughout the trial. For all groups, the body weight increased throughout the trial until day 35, without statistical significance. The bursa weight and the bursa to body weight ratio of the booster group was significant higher (p<0.05) than the non-booster and control groups. No gross and significant difference (p>0.05) of busa lesions scoring among all the groups. The antibody titre of groups ACH, BCH and CCH were higher than (p>0.05) groups A, B, and C but not significant. The antibody titre of group BCH was significantly higher (p<0.05) than groups ACH and BCH. Thus, it was concluded that the inactivated nVarIBDV is safe with booster dose (Group B) has a greater efficacy and able to induce humoral immune response

Item Type:	Project Paper
Faculty:	Faculty of Veterinary Medicine
Depositing User:	Ms Nurhaznita Mahmood
Date Deposited:	30 May 2024 07:47
Last Modified:	30 May 2024 07:47
URI:	http://psaspb.upm.edu.my/id/eprint/1844

Actions (login required)

View Item